Citalopram is a more potent platelet function inhibitor than paroxetine in a case-control study

Journal of Thrombosis and Haemostasis

Volumn 10, Issue 6, 2012, Pages 1177-1179

  van Holten, T C ^a   Roest, M ^a   Riphagen, J ^b   Jansen, C ^c   Naarding, P ^c   Adriaansen, H J ^b   de Groot, P G ^a   Remijn, J A ^b  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b GELRE HOSPITALS   (Netherlands)

^c GGNet Mental Health   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

15 HYDROXY 11ALPHA,9ALPHA EPOXYMETHANOPROSTA 5,13 DIENOIC ACID; CITALOPRAM; NORCITALOPRAM; PAROXETINE; SEROTONIN UPTAKE INHIBITOR; THROMBIN RECEPTOR ACTIVATING PEPTIDE;

ADULT; AGED; BLOOD SAMPLING; CASE CONTROL STUDY; CLINICAL ARTICLE; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG INHIBITION; DRUG MECHANISM; FEMALE; FLOW CYTOMETRY; HUMAN; LETTER; MALE; PRIORITY JOURNAL; THROMBOCYTE FUNCTION; TREATMENT RESPONSE;

ADULT; AGED; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; BLOOD PLATELETS; CASE-CONTROL STUDIES; CITALOPRAM; DOWN-REGULATION; FEMALE; HUMANS; MALE; MIDDLE AGED; NETHERLANDS; P-SELECTIN; PAROXETINE; PLATELET FUNCTION TESTS; SEROTONIN; SEROTONIN UPTAKE INHIBITORS;

EID: 84861666913     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/j.1538-7836.2012.04703.x     Document Type: Letter

References (22)

1. McNicol A, Israels SJ. Platelet dense granules: structure, function and implications for haemostasis. Thromb Res 1999; 95: 1-18.
2. Cohen RA, Shepherd JT, Vanhoutte PM. Inhibitory role of the endothelium in the response of isolated coronary arteries to platelets. Science 1983; 221: 273-4.
3. De Clerck F, Xhonneux B, Leysen J, Janssen PA. Evidence for functional 5-HT2 receptor sites on human blood platelets. Biochem Pharmacol 1984; 33: 2807-11.
4. Hergovich N, Aigner M, Eichler HG, Entlicher J, Drucker C, Jilma B. Paroxetine decreases platelet serotonin storage and platelet function in human beings. Clin Pharmacol Ther 2000; 68: 435-42.
5. Bismuth-Evenzal Y, Gonopolsky Y, Gurwitz D, Iancu I, Weizman A, Rehavi M. Decreased serotonin content and reduced agonist-induced aggregation in platelets of patients chronically medicated with SSRI drugs. J Affect Disord 2011; 136: 99-103.
6. McCloskey DJ, Postolache TT, Vittone BJ, Nghiem KL, Monsale JL, Wesley RA, Rick ME. Selective serotonin reuptake inhibitors: measurement of effect on platelet function. Transl Res 2008; 151: 168-72.
7. Kimmel SE, Schelleman H, Berlin JA, Oslin DW, Weinstein RB, Kinman JL, Sauer WH, Lewis JD. The effect of selective serotonin re-uptake inhibitors on the risk of myocardial infarction in a cohort of patients with depression. Br J Clin Pharmacol 2011; 72: 514-7.
8. Sauer WH, Berlin JA, Kimmel SE. Effect of antidepressants and their relative affinity for the serotonin transporter on the risk of myocardial infarction. Circulation 2003; 108: 32-6.
9. Sauer WH, Berlin JA, Kimmel SE. Selective serotonin reuptake inhibitors and myocardial infarction. Circulation 2001; 104: 1894-8.
10. Schlienger RG, Fischer LM, Jick H, Meier CR. Current use of selective serotonin reuptake inhibitors and risk of acute myocardial infarction. Drug Saf 2004; 27: 1157-65.
11. Meier CR, Schlienger RG, Jick H. Use of selective serotonin reuptake inhibitors and risk of developing first-time acute myocardial infarction. Br J Clin Pharmacol 2001; 52: 179-84.
12. Bak S, Tsiropoulos I, Kjærsgaard JO, Andersen M, Mellerup E, Hallas J, Rodríguez LAG, Christensen K, Gaist D. Selective serotonin reuptake inhibitors and the risk of stroke: a population-based case-control study. Stroke 2002; 33: 1465-73.
13. Andrade C, Sandarsh S, Chethan KB, Nagesh KS. Serotonin reuptake inhibitor antidepressants and abnormal bleeding: a review for clinicians and a reconsideration of mechanisms. J Clin Psychiatry 2009; 71: 1565-75.
14. Tseng YL, Chiang ML, Huang TF, Su KP, Lane HY, Lai YC. A selective serotonin reuptake inhibitor, citalopram, inhibits collagen-induced platelet aggregation and activation. Thromb Res 2010; 126: 517-23.
15. Galan AM, Lopez-Vilchez I, Diaz-Ricart M, Navalon F, Gomez E, Gasto C, Escolar G. Serotonergic mechanisms enhance platelet-mediated thrombogenicity. Thromb Haemost 2009; 102: 511-19.
16. Serebruany VL, Gurbel PA, O'Connor CM. Platelet inhibition by sertraline and N-desmethylsertraline: a possible missing link between depression, coronary events, and mortality benefits of selective serotonin reuptake inhibitors. Pharmacol Res 2001; 43: 453-62.
17. Serebruany VL, O'Connor CM, Gurbel PA. Effect of selective serotonin reuptake inhibitors on platelets in patients with coronary artery disease. Am J Cardiol 2001; 87: 1398-400.
18. Cipriani A, Furukawa TA, Salanti G, Geddes JR, Higgins JP, Churchill R, Watanabe N, Nakagawa A, Omori IM, McGuire H, Tansella M, Barbui C. Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis. Lancet 2009; 373: 746-58.
19. van Bladel ER, Roest M, de Groot PG, Schutgens RE. Up-regulation of platelet activation in hemophilia A. Haematologica 2011; 96: 888-95.
20. Maurer-Spurej E, Pittendreigh C, Solomons K. The influence of selective serotonin reuptake inhibitors on human platelet serotonin. Thromb Haemost 2004; 91: 119-28.
21. Atar D, Malinin A, Pokov A, van Zyl L, Frasure-Smith N, Lesperance F, Serebruany VL. Antiplatelet properties of escitalopram in patients with the metabolic syndrome: a dose-ranging in vitro study. Neuropsychopharmacology 2007; 32: 2369-74.
22. Musselman DL, Tomer A, Manatunga AK, Knight BT, Porter MR, Kasey S, Marzec U, Harker LA, Nemeroff CB. Exaggerated platelet reactivity in major depression. Am J Psychiatry 1996; 153: 1313-17.